News Novo's semaglutide outperforms Lilly GLP-1 rival If approved semaglutide could become set the standard for GLP-1 therapy
News Semaglutide could transform diabetes treatment, revive Novo ... Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
